Eliaz Therapeutics

Eliaz Therapeutics is a private, pre-revenue MedTech company pioneering a novel extracorporeal therapy targeting Galectin-3 (Gal-3), a protein implicated in sepsis, kidney disease, fibrosis, and cancer progression. Its lead asset, the XGal-3® apheresis column, has received FDA Breakthrough Device Designation for sepsis and is supported by NIH funding and a strategic manufacturing collaboration with Terumo BCT. The company's platform technology aims to create a new standard of care in critical care and chronic disease by physically removing a root-cause inflammatory driver, leveraging existing hospital infrastructure for potential rapid adoption.

The XGal-3® apheresis column, a medical device designed for use with standard apheresis systems to selectively remove the pathogenic protein Galectin-3 (Gal-3) from blood plasma. It uses a proprietary affinity ligand to bind and extract Gal-3, targeting a root-cause driver of inflammation and fibrosis in acute and chronic diseases.

Eliaz appears first-in-class with an extracorporeal Gal-3 removal device. Direct competitors are limited, but it faces indirect competition from broad-spectrum blood purification devices (e.g., CytoSorb) and future drug developers targeting Gal-3 inhibition. Its key differentiator is the specific targeting of a well-validated protein using familiar apheresis infrastructure.